ENTRAPMENT NEUROPATHIES: RATIONALE FOR PATHOGENETIC THERAPY

Abstract

The paper describes the pathogenesis of entrapment or compression-and-ischemic neuropathies, by providing a rationale for pathogenetic therapy. It gives the clinical manifestations of tunnel syndromes and methods for their diagnosis and treatment. The author dwells upon the use of Milgamma compositum that contains 100 mg of benfotiamine and 100 mg of pyridoxine. These two neutropic components of the drug improve the speed of nerve impulse conduction and enhance the capability of the nerve for regeneration.